Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 4

2(66.7%)

Phase 1

1(33.3%)

3Total

Phase 4(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07312734Not Yet Recruiting

Study to Enable New Diagnostics for Pulmonary Microbes in People With CF

Role: lead

NCT04294043Phase 1Recruiting

IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)

Role: lead

NCT03801993Completed

Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis

Role: lead

NCT05548283Phase 4Recruiting

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

Role: lead

NCT05285410Completed

Observational Study Comparing Home to Office Spirometry

Role: lead

NCT02781610Phase 4Completed

Standardized Treatment of Pulmonary Exacerbations II

Role: lead

All 6 trials loaded